REGENXBIO Inc. Operating Lease Right-of-Use Assets
REGENXBIO Inc. (RGNX) had Operating Lease Right-of-Use Assets of $43.87 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Operating Lease, Right-of-Use Asset $43.87M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $45.54M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $47.16M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $48.82M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $43.87M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $45.54M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $47.16M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $48.82M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $50.47M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $52.11M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $53.72M 10-K · filed 2026-03-05 |
| 2024-09-30 | $55.29M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $56.34M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $57.56M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $60.49M 10-K · filed 2025-03-13 |
| 2023-09-30 | $61.77M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $62.44M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $63.73M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $65.12M 10-K · filed 2024-02-27 |
| 2022-09-30 | $59.47M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $60.16M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $59.92M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $60.90M 10-K · filed 2023-02-28 |
| 2021-09-30 | $61.74M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $62.28M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $62.61M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $63.81M 10-K · filed 2022-03-01 |
| 2020-09-30 | $57.83M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $8.63M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $9.38M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $10.08M 10-K · filed 2021-03-01 |
| 2019-09-30 | $5.91M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $5.90M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $6.86M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |